[{"id":"d1651a97-e0b7-453b-880d-d4d563121330","acronym":"","url":"https://clinicaltrials.gov/study/NCT06834373","created_at":"2025-02-25T13:57:53.594Z","updated_at":"2025-02-25T13:57:53.594Z","phase":"Phase 2","brief_title":"Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy","source_id_and_acronym":"NCT06834373","lead_sponsor":"Mayo Clinic","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/03/2025","start_date":" 03/03/2025","primary_txt":" Primary completion: 03/03/2027","primary_completion_date":" 03/03/2027","study_txt":" Completion: 03/03/2027","study_completion_date":" 03/03/2027","last_update_posted":"2025-02-20"},{"id":"ffcc36de-86c4-4efe-bf14-26220583e249","acronym":"TOP-FLOR","url":"https://clinicaltrials.gov/study/NCT05788081","created_at":"2023-03-28T14:05:15.158Z","updated_at":"2025-02-25T14:17:47.899Z","phase":"Phase 2","brief_title":"Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.","source_id_and_acronym":"NCT05788081 - TOP-FLOR","lead_sponsor":"Olivia Newton-John Cancer Research Institute","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive • LDH elevation","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Rituxan (rituximab) • golcadomide (CC-99282)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/31/2023","start_date":" 08/31/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-06-26"},{"id":"642bd716-2adc-4e1e-9e83-d1fcc5dbe602","acronym":"","url":"https://clinicaltrials.gov/study/NCT02417285","created_at":"2021-03-25T18:07:07.062Z","updated_at":"2024-07-02T16:35:32.080Z","phase":"Phase 1b","brief_title":"A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.","source_id_and_acronym":"NCT02417285","lead_sponsor":"Celgene","biomarkers":" MYC • BCL2 • CD20","pipe":" | ","alterations":" CD20 positive • MYC overexpression • MYC rearrangement","tags":["MYC • BCL2 • CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • MYC overexpression • MYC rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • avadomide (CC-122)"],"overall_status":"Completed","enrollment":" Enrollment 75","initiation":"Initiation: 05/22/2015","start_date":" 05/22/2015","primary_txt":" Primary completion: 05/27/2019","primary_completion_date":" 05/27/2019","study_txt":" Completion: 09/28/2023","study_completion_date":" 09/28/2023","last_update_posted":"2023-10-23"},{"id":"1e4b2de0-7598-443a-8427-00e8018ce0a7","acronym":"ENHANCE","url":"https://clinicaltrials.gov/study/NCT02406742","created_at":"2021-01-18T11:29:32.160Z","updated_at":"2024-07-02T16:36:24.261Z","phase":"Phase 1/2","brief_title":"A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT02406742 - ENHANCE","lead_sponsor":"Celgene","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • avadomide (CC-122)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 07/27/2015","start_date":" 07/27/2015","primary_txt":" Primary completion: 07/07/2020","primary_completion_date":" 07/07/2020","study_txt":" Completion: 07/07/2020","study_completion_date":" 07/07/2020","last_update_posted":"2021-09-20"},{"id":"205cd8dd-a7f0-4f56-8d9f-9bea73d31597","acronym":"","url":"https://clinicaltrials.gov/study/NCT03283202","created_at":"2021-01-18T16:13:06.990Z","updated_at":"2024-07-02T16:36:30.991Z","phase":"Phase 1/2","brief_title":"Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors","source_id_and_acronym":"NCT03283202","lead_sponsor":"Celgene","biomarkers":" CD20","pipe":" | ","alterations":" LDH elevation","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • avadomide (CC-122) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 10/04/2017","start_date":" 10/04/2017","primary_txt":" Primary completion: 07/30/2019","primary_completion_date":" 07/30/2019","study_txt":" Completion: 12/16/2020","study_completion_date":" 12/16/2020","last_update_posted":"2021-04-29"}]